Patients opinion and adherence to antimalarials in lupus erythematosus and rheumatoid arthritis treatment

Cabral, Renata Tavares de Souza; Klumb, Evandro Mendes; Carneiro, Sueli

doi:10.1080/09546634.2019.1595504

Cited by 5 publications

(4 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The choice between CQ and HCQ depended on the disease's activity, availability of medicine, and treating physician. In our study, 86% of patients received CQ, while in the report by Cabral et al 55% of patients were treated with HCQ and 25% with CQ (Cabral et al, 2019).…”

Section: Pharmacological Treatment and Adverse Eventscontrasting

confidence: 49%

Adverse events in rheumatoid arthritis patients under antimalarial treatment—Is there cardiovascular compromise?

Santos-Moreno¹,

Ibatá²,

Martínez³

et al. 2023

Front. Drug Saf. Regul.

View full text Add to dashboard Cite

Introduction: The antimalarials chloroquine and hydroxychloroquine have been used for several decades in treating malaria and some autoimmune diseases—mainly rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE)—with excellent efficacy and safety. Due to the massive use of antimalarials worldwide for managing SARS-CoV-2/COVID-19 infection during the last 2 years and the consequent increase in cardiac arrhythmia, fear has risen about the safety of using antimalarials, especially for patients with increased cardiovascular risk.Objective: To describe a real-life experience about the safety of antimalarials in the setting of a single rheumatological center in Colombia.Methods: This is a cross sectional study that includes patients diagnosed with RA and treated with antimalarials between 2020 and 2021. Clinical follow-up information was gathered from the medical records, and all reported adverse events were described.Results: A total of 957 patients were included, primarily women (79.2%). The most frequent comorbidities were hypertension and osteoporosis. Chloroquine use was more frequent than hydroxychloroquine (86.4% vs. 13.6%). During the observation period, 243 (25.4%) patients presented at least one adverse event, 72 (29.6%) had retinal toxicity, 85 (35%) dermatological events, and 81 (33.3%) gastrointestinal intolerance. Other adverse events reported less frequently (15.2%) included headache, dizziness, lipothymia, and elevated transaminases. There were no reports of cardiovascular events from the period of antimalarial use to the date of data collection despite the high frequency of previous metabolic or cardiovascular disease in this cohort.Conclusion: This study reasserts the evidence of antimalarials safety profile for patients with rheumatological conditions such as RA. RA patients that were treated with antimalarials at doses recommended by the guidelines had no cardiovascular events.

show abstract

Section: Pharmacological Treatment and Adverse Eventscontrasting

confidence: 49%

Adverse events in rheumatoid arthritis patients under antimalarial treatment—Is there cardiovascular compromise?

Santos-Moreno¹,

Ibatá²,

Martínez³

et al. 2023

Front. Drug Saf. Regul.

View full text Add to dashboard Cite

show abstract

“…Since then, multiple studies have shown high levels of very poor adherence, generally ranging from 20% to 50% of patients 38,39,40,41,42 . Common reasons for poor adherence cited by patients include fear of adverse effects and lack of understanding of the benefits 32,43 . Is it possible that part of the mad scramble at pharmacies for HCQ comes from our "legacy" patients who suddenly want to fill their previously neglected HCQ prescription?…”

Section: Rheumatologymentioning

confidence: 99%

Possible Consequences of a Shortage of Hydroxychloroquine for Patients with Systemic Lupus Erythematosus amid the COVID-19 Pandemic

Peschken

2020

J Rheumatol

View full text Add to dashboard Cite

“…The questionnaire was a modified version of a previously published study by Cabral et al (2020) [ 9 ]. It was translated using the standard method (forward/backward translation by two independent translators) to ensure the accuracy of the translation.…”

Section: Methodsmentioning

confidence: 99%

Knowledge of Saudi Patients with Autoimmune Diseases about Hydroxychloroquine Toxicity: The Role of Physician–Patient Communication

et al. 2022

View full text Add to dashboard Cite

This cross-sectional internet-based questionnaire aimed to assess the knowledge and experience of autoimmune disease patients in Saudi Arabia of the ocular effects of hydroxychloroquine (HCQ). Among the 245 respondents, discontinuation of the drug was linked to its ocular toxicity in approximately 7.3%. Most patients had taken HCQ for a period longer than five years, exceeding a dose of 5 mg/Kg. A lack of education and physician communication about medication toxicity was reported by approximately 40.8% of the participants. Despite the knowledge about HCQ retinopathy, the drug is prescribed to autoimmune disease patients at an inappropriate dosage. Knowledge obtained from physicians’ communication may improve the health outcomes of chronically ill patients. Rheumatologists and ophthalmologists should work together to recognize patients at risk of hydroxychloroquine toxicity and ensure they receive proper education and adhere to periodic follow-up.

show abstract

Patients opinion and adherence to antimalarials in lupus erythematosus and rheumatoid arthritis treatment

Cited by 5 publications

References 24 publications

Adverse events in rheumatoid arthritis patients under antimalarial treatment—Is there cardiovascular compromise?

Adverse events in rheumatoid arthritis patients under antimalarial treatment—Is there cardiovascular compromise?

Possible Consequences of a Shortage of Hydroxychloroquine for Patients with Systemic Lupus Erythematosus amid the COVID-19 Pandemic

Knowledge of Saudi Patients with Autoimmune Diseases about Hydroxychloroquine Toxicity: The Role of Physician–Patient Communication

Contact Info

Product

Resources

About